# ASP Isotopes Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ASP Isotopes Inc.).

## Overview

ASP Isotopes Inc. is a development-stage advanced materials company built around proprietary isotope-separation technologies, including Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE). The company is focused on producing high-value, low-volume isotopes for specialized end markets such as pharmaceuticals, agrochemicals, nuclear medical imaging, and semiconductors. It also has a separate nuclear fuels business through Quantum Leap Energy (QLE), which is being developed around HALEU and Lithium-6 for advanced nuclear applications. In 2025, the company expanded further into construction services through its Skyline acquisition, adding a third operating segment alongside specialist isotopes and nuclear fuels.

## Products & services

• Enriched specialist isotopes (C-14, Mo-100, Si-28, Yb-176)
• Nuclear medical doses for PET scanning
• Advanced nuclear fuels (HALEU, Lithium-6)
• Isotope separation technology and related R&D services
• Construction services for roads and drainage in Hong Kong

- **Specialist isotopes and related services** (35%) — Development and commercialization of high-value, low-volume isotopes and related services for medical, industrial, and semiconductor uses.
- **Nuclear fuels** (5%) — Research, development, and commercialization of advanced nuclear fuel products such as HALEU and Lithium-6 through QLE.
- **Nuclear medical doses** (20%) — Production and sale of PET scanning doses used in nuclear medical imaging, primarily through PET Labs in South Africa.
- **Construction services** (40%) — Civil engineering and subcontracted construction work, including road and drainage projects in Hong Kong via Skyline.

- Enriched specialist isotopes (C-14, Mo-100, Si-28, Yb-176)
- Nuclear medical doses for PET scanning
- Advanced nuclear fuels (HALEU, Lithium-6)
- Isotope separation technology and related R&D services
- Construction services for roads and drainage in Hong Kong

## Customers

ASP Isotopes serves highly specialized customers that need isotopes with precise enrichment, purity, and supply reliability. Its specialist isotope products are aimed at pharmaceutical and agrochemical users, nuclear medical imaging applications, and semiconductor-related uses, where the isotopes are inputs to research, diagnostics, or manufacturing. The nuclear fuels business is targeted at advanced nuclear developers and potential strategic partners seeking HALEU and Lithium-6 supply. The PET medical dose business serves healthcare and imaging customers in South Africa, while the construction segment serves public-sector and infrastructure clients in Hong Kong through civil engineering projects.

- **Specialty isotope end users** (primary) — Buy enriched isotopes such as C-14, Mo-100, Si-28, and Yb-176 for pharmaceutical, agrochemical, semiconductor, and research applications.
- **Advanced nuclear fuel developers** (secondary) — Seek HALEU and Lithium-6 products and related development capabilities for next-generation nuclear fuel supply chains.
- **PET imaging and nuclear medicine customers** (secondary) — Purchase nuclear medical doses used in PET scanning, supporting diagnostic imaging workflows in South Africa.
- **Public infrastructure and civil engineering clients** (secondary) — Buy road, drainage, and related civil engineering services in Hong Kong through Skyline/Kin Chiu Engineering.

- Pharmaceutical and agrochemical users needing enriched isotopes for specialized applications
- Nuclear medical imaging customers buying PET scanning doses
- Advanced nuclear fuel customers seeking HALEU and Lithium-6 supply
- Semiconductor and materials science customers using isotopes such as Si-28
- Public civil engineering clients in Hong Kong for road and drainage works
- Subcontracting partners and main contractors on infrastructure projects

## Geography

ASP Isotopes operates through subsidiaries in the United Kingdom, South Africa, Iceland, the Cayman Islands, and Guernsey, with the UK entity owning the core technology. The company’s commercial activity is split across multiple geographies: specialist isotope development is managed through its international subsidiary structure, PET dose revenue is recognized in South Africa, and construction services were added in Hong Kong after the Skyline acquisition. The nuclear fuels business is also organized through UK and South African subsidiaries, reflecting the company’s intention to build production and commercialization capabilities in jurisdictions relevant to nuclear and industrial supply chains. Geography matters because the business depends on local regulatory approvals, specialized manufacturing and production sites, and cross-border supply chain execution.

- United States is the parent company domicile and capital markets base
- United Kingdom houses the technology owner and part of the nuclear fuels structure
- South Africa is important for PET dose production and isotope-related operations
- Hong Kong contributes construction revenue through Skyline/Kin Chiu Engineering
- Cayman Islands, Guernsey, and Iceland are part of the subsidiary structure
- Cross-border operations increase regulatory and execution complexity

## Strategy

ASP Isotopes is trying to commercialize proprietary isotope-enrichment technologies while still in a development-stage phase, so its strategy centers on moving selected products from R&D into production and sales. The company’s initial focus remains on enriched isotopes such as C-14, Si-28, and Yb-176, while QLE is being built separately around advanced nuclear fuels like HALEU and Lithium-6. Management has also signaled a possible spin-out of QLE, which would separate the nuclear fuels business from the medical and specialist isotope platform and allow each business to be financed and managed independently. The Skyline acquisition adds a third operating line, giving the group a revenue-generating construction business while the core isotope businesses continue to scale.

- **Commercialize specialist isotopes** (short-term) — The company needs to convert R&D into repeatable production and sales to create a durable revenue base.
- **Build the QLE nuclear fuels platform** (medium-term) — HALEU and Lithium-6 could become strategically important products in advanced nuclear supply chains.
- **Separate and finance businesses independently** (medium-term) — A spin-out could align capital allocation with distinct regulatory and commercial profiles across business lines.
- **Grow operating revenue through acquisitions** (short-term) — Adding revenue-generating businesses can reduce dependence on pre-commercial isotope development.

- Commercialize proprietary isotope-separation technologies
- Scale production of enriched isotopes for specialized end markets
- Develop HALEU and Lithium-6 through the QLE platform
- Potentially spin out QLE as a separate public company
- Use acquisitions to add operating revenue and capabilities
- Expand PET dose production capacity in South Africa

## Risks

ASP Isotopes faces substantial execution risk because most of its core isotope businesses are still in development and have not yet produced meaningful commercial revenue. The company’s ability to reach profitability depends on successful scale-up, regulatory approvals, and commercialization of enriched isotopes and nuclear fuel products, all of which are technically complex and capital intensive. Its business is also exposed to fair value volatility from convertible notes and other financing instruments, reflecting a funding model that has relied on equity and debt issuance rather than operating cash flow. In addition, the new construction segment introduces project execution, subcontracting, and margin risks, while the company’s cross-border footprint exposes it to trade policy, inflation, foreign exchange, and jurisdiction-specific regulatory risk.

- **Failure to commercialize enriched isotopes** [critical] — The company has not yet generated revenue from enriched isotopes, so the core business depends on successful development and scale-up.
- **Regulatory and licensing delays in nuclear fuels** [high] — HALEU and Lithium-6 production is subject to a more complex regulatory landscape than medical isotopes.
- **Financing and dilution risk** [high] — Operations have been funded mainly through equity and convertible notes, and future development will likely require additional capital.
- **Fair value volatility on convertible notes** [high] — Changes in the fair value of convertible notes can materially affect reported earnings and obscure operating performance.
- **Construction execution and subcontracting risk** [medium] — The Skyline business depends on project delivery, subcontractor performance, and cost control on civil engineering contracts.
- **Trade policy, inflation, and foreign exchange** [medium] — The company operates across multiple jurisdictions and imports/exports specialized materials and services.

- Commercialization may fail or take longer than expected for enriched isotopes
- Regulatory approvals can delay nuclear fuel and isotope production plans
- Funding needs remain high because the company has not yet generated isotope revenue
- Convertible notes and fair value remeasurement can create earnings volatility
- Construction services add project execution and subcontracting risk
- Cross-border operations expose the company to trade policy, inflation, and FX risk

## Accounting

ASP Isotopes has several accounting areas that can materially affect reported results because the business mix includes development-stage R&D, early-stage product sales, and construction contracts. Revenue recognition differs by segment: PET dose sales are recognized when the nuclear medical doses are sold, while construction revenue depends on contract performance and project execution, which can create timing differences between work performed and cash collected. The company also records significant fair value changes on convertible notes payable and share liabilities, which can create large non-operating swings in earnings unrelated to underlying operations. In addition, capitalized prepayments for R&D, lease accounting for production facilities, and potential impairment or valuation issues tied to acquired businesses and development assets require judgment and can affect comparability across periods.

- **Revenue recognition by segment** — Revenue timing and gross margin
- **Fair value of convertible notes payable** — Net loss volatility
- **Share liability and equity-linked awards** — Other income/expense
- **R&D expense recognition** — Operating loss
- **Lease accounting** — EBITDA and lease obligations

- Revenue recognition differs between PET dose sales and construction services
- Construction contracts can create timing differences in revenue and margin recognition
- Fair value remeasurement of convertible notes can materially affect net loss
- Share-based liabilities and consultant equity awards add valuation volatility
- R&D spending is expensed as incurred, while some prepayments are capitalized until received
- Lease accounting affects production facility costs and operating expense timing

---

*Last updated: 2026-08-11T04:46:18.866893+00:00*